Loading...
•
Dec 31, 2025
Outlook Therapeutics Q1 2026 Earnings Report
Outlook Therapeutics reported first quarter fiscal year 2026 results with increased European commercial activity and a net loss driven by non-cash fair value adjustments.
Key Takeaways
Outlook Therapeutics reported net revenue of -1208000 for Q1 fiscal 2026, reflecting product return reserves related to its European launch. The company posted a net loss of 23058000, while continuing expansion of LYTENAVA in Europe and engaging with the FDA regarding ONS-5010 in the U.S.
Net revenue was -1208000 for the quarter due to increased returns reserves tied to UK distributor shipments.
Net loss attributable to common stockholders was 23058000, or 0.38 per share.
Cash and cash equivalents totaled 8677000 as of December 31, 2025.
Weighted average diluted shares outstanding were 60205000.
Revenue by Geographic Location
Forward Guidance
The company expects continued European expansion of LYTENAVA in 2026 and is pursuing regulatory engagement with the FDA to address the CRL for ONS-5010 in the United States.
Positive Outlook
- Commercial launch completed in Austria in January 2026.
- Additional European launches planned in Ireland and the Netherlands in 2026.
- Unit sales in Europe more than doubled quarter-over-quarter.
- Type A meeting request submitted to the FDA to address CRL.
- Marketing Authorization secured in EU and UK for LYTENAVA.
Challenges Ahead
- Negative revenue impact from increased product return reserves.
- Ongoing net losses and limited cash balance.
- CRL received from FDA requiring additional confirmatory evidence.
- Dependence on regulatory outcomes in the U.S.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...